X

Sequent Scientific Ltd Stock Analysis

Mid Cap
Evaluated by 1136 users | BSE: 512529 | NSE: SEQUENT |
Pharmaceuticals & Drugs
P I Drugs & Pharmaceuticals Ltd. established in 1991 is a leading manufacturer, exporter of specialized quality formulations having an objective of fulfilling the diverse demands of pharmaceutical industry.P I Drugs & Pharmaceuticals Ltd. specializes in the manufacturing of the...
1. Right Stock
Very Good
2. Right Price
3. Right Time

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sequent Scientific Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation
Value Creation Index Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 6%7.28%-8.95%-8.28%-1.14%0.66%1.18%13.83%7.43%8.99%
Value Creation Index -0.48-0.37-1.78-1.72-1.10-0.94-0.900.20-0.35-0.22
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 3123463274554656256841,0311,0391,179
Y-o-Y Gr. Rt.-10.9%-5.5%39.4%2.2%34.3%9.4%50.8%0.9%13.5%
Adjusted EPS (Rs.) 0.130.44-4.95-4.7-2.48-0.86-0.175.672.172.96
Y-o-Y Gr. Rt.-238.5%-1225%NANANANANA-61.7%36.4%
Book Value per Share (Rs.) 11.5911.487.091.973.7638.6939.4425.8527.8629.34
Adjusted Net Profit 1.44.9-59.5-64.2-37.8-20.5-4.113853.673.4
Net Op. Cash Flow (Rs. Cr.) 49.621.5-3.8-44.8-23.6-0.1-7.245.2116115
Debt to Cash Flow from Ops 3.8212.51-81.46-9.34-20.1-5,782.48-57.816.732.82.87
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Sequent Scientific Ltd. should be analysed on a Consolidated basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 15.9%20.4%19.9%13.5%
Adjusted EPS 41.5%NANA36.4%
Book Value per Share 10.950.8-9.45.3
Share Price 37.1% 6% 40.1% 190.5%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 1.223.95-54.74-84.6-51.12-3.96-0.43177.9110.13
Operating Profit Margin (%) 14.6515.21-2.395.664.719.528.1311.2212.7714.91
Net Profit Margin (%) -0.771.39-18.21-14.09-8.35-2.95-0.9714.35.957.25
Debt to Equity 1.542.193.7415.868.260.340.430.480.470.45
Working Capital Days 208223251210233224314226206189
Cash Conversion Cycle 389613617693707973
Corporate Governance What do we look at?
Corporate Governance
Board Credentials
Promoter's holding
Transparency
Integrity
Entity Percentage Holding
Promoters 53.86%
Institutions 14.84%
Non-Institutions 31.30%
Pledged *43.0244.5643.0641.8270.7262.1271.4144.600.000.00
* Pledged shares as % of Promoter's holding (%)

MoneyWorks4Me analysed the past 10-year performance of Sequent Scientific Ltd and arrived at the following conclusion:

Past 10 year's financial track record indicates that Sequent Scientific Ltd is a average quality company. However, for specific investment actions please connect with your investment advisor.

The 5-year analysis of Sequent Scientific Ltd's performance infers:

Sequent Scientific Ltd earnings have grown by 0%, whereas share price has appreciated 6% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Sequent Scientific Ltd share prices over the last 10 years. Here is what we found out:

Sequent Scientific Ltd share price has appreciated 32.3% annually over the past ten years.

P I Drugs & Pharmaceuticals Ltd. established in 1991 is a leading manufacturer, exporter of specialized quality formulations having an objective of fulfilling the diverse demands of pharmaceutical industry.

P I Drugs & Pharmaceuticals Ltd. specializes in the manufacturing of the formulation belonging to anthelmintic & anti-parasitic segment.

In September 2007 PI Drugs purchased the pharma division of Transchem Limited.

The company is engaged in the business of human health

P I Drugs & Pharmaceuticals Ltd. established in 1991 is a leading manufacturer, exporter of specialized quality formulations having an objective of fulfilling the diverse demands of pharmaceutical industry.

P I Drugs & Pharmaceuticals Ltd. specializes in the manufacturing of the formulation belonging to anthelmintic & anti-parasitic segment.

In September 2007 PI Drugs purchased the pharma division of Transchem Limited.

The company is engaged in the business of human health & animal health and enjoys high Image for distribution in domestic as well as international markets.

They have a specialized and dedicated WHO - GMP accredited manufacturing plant for the manufacture of API's. It exports to all major markets like Europe, South America, Australia, Asia and Africa.

They started with the introduction of Albendazole and has developed core competency in chemistry of Benzimadazole in very short time.

Product range of the company includes:

Human / Veterinary Formulations

  • Diminazene Diaceturate
  • Toldimfos Sodium
  • Quinapyramine
  • Triclabendazole
  • Albendazole
  • Fenbendazole
  • Oxyclozanide
  • Niclosamide
  • Frusemide
  • Mebendazole

Honey Bee Medicine

  • Pizitol®
  • Apistonic®
  • Transprim®

Human / Veterinary API's

Veterinary API’s

  • Albendazole USP/EP/BP
  • Fenbendazole BP/ EP/BP VET
  • Oxfendazole EP/BP VET
  • Mebendazole USP/EP/BP/POLY 'C'

Human API's 

  •  Pentamidine Isethionate
  •  Ramipril EP / BP
  •  Frusemide USP / EP / BE
  •  Cetrizine DI HCL BP / EP
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback